Related Experiment Video
Updated: Jul 8, 2026

Real-time Imaging of Myeloid Cells Dynamics in ApcMin/+ Intestinal Tumors by Spinning Disk Confocal Microscopy
Published on: October 6, 2014
Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome
Thomas E Sussan1, Annan Yang, Fu Li
1Department of Physiology and The Institute for Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
Abstract:
Epidemiological studies spanning more than 50 yr reach conflicting conclusions as to whether there is a lower incidence of solid tumours in people with trisomy 21 (Down's syndrome). We used mouse models of Down's syndrome and of cancer in a biological approach to investigate the relationship between trisomy and the incidence of intestinal tumours. Apc(Min)-mediated tumour number was determined in aneuploid mouse models Ts65Dn, Ts1Rhr and Ms1Rhr. Trisomy for orthologues of about half of the genes on chromosome 21 (Hsa21) in Ts65Dn mice or just 33 of these genes in Ts1Rhr mice resulted in a significant reduction in the number of intestinal tumours. In Ms1Rhr, segmental monosomy for the same 33 genes that are triplicated in Ts1Rhr resulted in an increased number of tumours. Further studies demonstrated that the Ets2 gene contributed most of the dosage-sensitive effect on intestinal tumour number. The action of Ets2 as a repressor when it is overexpressed differs from tumour suppression, which requires normal gene function to prevent cellular transformation. Upregulation of Ets2 and, potentially, other genes involved in this kind of protective effect may provide a prophylactic effect in all individuals, regardless of ploidy.
Insights
Individuals with Down's syndrome (trisomy 21) may have a lower incidence of intestinal tumors. Mouse models show trisomy, particularly involving the Ets2 gene, significantly reduces tumor development, suggesting a potential prophylactic effect.
Area of Science:
- Genetics
- Cancer Biology
- Developmental Biology
Background:
- Epidemiological studies on cancer incidence in Down's syndrome (trisomy 21) yield conflicting results.
- Understanding the biological basis of cancer risk in aneuploidy is crucial.
Purpose of the Study:
- To investigate the relationship between trisomy and intestinal tumor incidence using mouse models.
- To determine if trisomy influences Apc(Min)-mediated intestinal tumor development.
Main Methods:
- Utilized aneuploid mouse models (Ts65Dn, Ts1Rhr, Ms1Rhr) mimicking aspects of Down's syndrome.
- Quantified Apc(Min)-mediated intestinal tumor numbers in these models.
- Analyzed the role of specific genes, including Ets2, in dosage-sensitive effects on tumor development.
Main Results:
- Trisomy for human chromosome 21 orthologues in Ts65Dn and Ts1Rhr mice significantly reduced intestinal tumor numbers.
- Monosomy for the same genes in Ms1Rhr mice increased tumor numbers.
- The Ets2 gene was identified as a major contributor to the dosage-sensitive effect on tumor incidence.
Conclusions:
- Trisomy, specifically involving Ets2, confers a protective effect against intestinal tumor development.
- Overexpression of Ets2 acts as a repressor, distinct from traditional tumor suppression.
- Upregulation of Ets2 and related genes may offer a prophylactic effect against cancer, irrespective of ploidy.
Related Concept Videos
Abnormal Proliferation
X-Inactivation
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Replicative Cell Senescence
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Meiosis I

